Humabs BioMed is a subsidiary of Vir Biotechnology, please click on the link below to go to Vir Bio’s website or you will be automatically redirected after 10 seconds.


Visit Vir Biotechnology

Humabs
Developing Potent and Specific Immunotherapies
to Fight Life
Threatening Infections
Humabs is using its cutting-edge proprietary CellClone technologies to discover effective new treatments against a variety of viral and bacterial infections.

The Company’s focus is discovering and developing anti-infective immunotherapies up to clinical proof of concept.
Humabs has also a portfolio of programs to address major public health threats, such as Ebola, Zika, Rabies and Dengue.

Highlights
  • Subsidiary of Vir Biotechnology, a San Francisco-based company, integrating diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases, including treatment that induce protective and therapeutic immune responses which solutions are non-existent or inadequate. 
  • Promising development programs address areas of major unmet medical need, including chronic hepatitis B, respiratory syncytial virus/ metapneumovirus (RSV/MPV) infections and congenital Zika virus infections
  • Cutting-edge, proprietary CellClone discovery platforms enable high-quality lead generation to further expand the internal development portfolio
  • Public Health portfolio to address major public health concerns being developed in cooperation with government and not-for-profit health organizations
Latest
news
go
CellClone
CellClone
technologies
go

The potential of Humabs’ CellClone technology is supported by a rich pipeline.

Humabs has developed a unique and comprehensive approach for screening and selecting highly effective naturally occurring human antibodies.
The technology originates from the laboratory of Prof. Antonio Lanzavecchia, Director of the Institute for Research in Biomedicine (IRB) in Switzerland and scientific founder of Humabs. Utilizing Humabs’ proprietary CellClone technologies, human monoclonal antibodies are isolated from memory B cells and plasma cells derived from convalescent patients. Ultra-potent antibodies are rapidly identified, engineered and developed for prophylactic, therapeutic or diagnostic purposes.
Development Pipeline
go
Development Pipeline

With more than fifteen development candidates, Humabs has a broad and varied pipeline, internal and public health programs. These anti-infective immunotherapy candidates are being developed to treat a number of viral and bacterial diseases.

Humabs has a successful track record of advancing its leads through the early stages of development.
Humabs
Humabs BioMed SA
Via dei Gaggini 3
CH-6500 Bellinzona
Switzerland
info@humabs.com
T +41 91 825 63 80
F +41 91 825 64 92